The Journal of Contemporary Dental Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 16 , ISSUE 7 ( July, 2015 ) > List of Articles

REVIEW ARTICLE

Inflammation and Oral Cancer: An Update Review on Targeted Therapies

Shankar Gouda Patil, Anuprita Patil, Rahul Anand

Citation Information : Patil SG, Patil A, Anand R. Inflammation and Oral Cancer: An Update Review on Targeted Therapies. J Contemp Dent Pract 2015; 16 (7):595-602.

DOI: 10.5005/jp-journals-10024-1727

Published Online: 00-07-2015

Copyright Statement:  Copyright © 2015; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Sarode GS, Sarode SC, Patil A, Anand R, Patil SG, Rao RS, Augustine D. Inflammation and Oral Cancer: An Update Review on Targeted Therapies. J Contemp Dent Pract 2015;16(7):595-602.


PDF Share
  1. Head and neck cancer. N Engl J Med 1993;328(3):184-194.
  2. Recent advances in epidemiology of head and neck cancer. Curr Opin Oncol 1992;4(3):471-477.
  3. Oral cancers in India. Semin Oncol 2001;28(2):169-173.
  4. Early detection of oral cancer: detector lies within. Oral Oncol 2012;48(3):193-194.
  5. OP(Oral Pathologist)inion matters. Oral Oncol 2012;48(11):e47-48.
  6. Criteria to define true second primary oral squamous cell carcinoma. Oral Oncol 2010;46(11):834.
  7. STAT signaling in head and neck cancer. Oncogene 2000;19(15):2489-2495.
  8. Multiple primary malignant tumors in patients with head and neck cancer: results of a prospective study and future perspectives. Laryngoscope 1998;108(2):250-256.
  9. The molecular biology of oral carcinogenesis: toward a tumor progression model. J Oral Maxillofac Surg 1997;55(6):613-623.
  10. Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 2000;53(4):165-172.
  11. Cell death regulation in oral squamous cell carcinoma: methodological considerations and clinical significance. J Oral Pathol Med 2003;32(3):125-138.
  12. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30(7):1073-1081.
  13. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7(3):211-217.
  14. Inflammation in the context of oral cancer. Oral Oncol 2013;49(9):887-892.
  15. A new classification for potentially malignant disorders of the oral cavity. Oral Oncol 2011;47(9):920-921.
  16. Oral potentially malignant disorders: precising the definition. Oral Oncol 2012;48(9):759-760.
  17. Oral (mucosal) potentially malignant disorders. Oral Oncol 2012;48(10):e35-36.
  18. Distinct role of intrarenal cyclooxygenase-1/2 in chronic unilateral renal ischemia. Nephron 2002;92(1):183-191.
  19. Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma. Histopathology 2010;57(1):90-100.
  20. The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. J Exp Clin Cancer Res 2011;30:13.
  21. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57(7):1276-1280.
  22. Immunity, inflammation, and cancer. Cell 2010;140(6):883-899.
  23. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29(6):781-788.
  24. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10(17):5930-5939.
  25. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 2001;92(7):1888-1895.
  26. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila) 2008;1(5):339-348.
  27. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14(7):2095-2101.
  28. Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 1996;106(2):129-134.
  29. Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 2008;23(10):1269-1278.
  30. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositidedependent protein kinase-1 inhibitors. Cancer Res 2004;64(12):4309-4318.
  31. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 2005;7(5):R 796-807.
  32. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005;11(17):6261-6269.
  33. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005;4(9):1448-1455.
  34. Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase 1b and Pharmacokinetic Study. Cancer Prev Res (Phila) 2014 Mar;7(3):283-291.
  35. CTGF inhibits cell motility and COX-2 expression in oral cancer cells. Int Immunopharmacol 2011;11(8):948-954.
  36. CCN proteins: multifunctional signalling regulators. Lancet 2004;363(9402):62-64.
  37. MAP kinases: charting the regulatory pathways. Science 1992;257(5075):1355-1356.
  38. Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint. EMBO J 2006;25(4):763-773.
  39. Quantification of p38alphaMAP kinase: a prognostic marker in HNSCC with respect to radiation therapy. Clin Chim Acta 2012;413(1):219-225.
  40. Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38α MAP kinase. Biochim Biophys Acta 2013;1830(3):2763-2769.
  41. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8(4):945-954.
  42. The STATs of cancer.new molecular targets come of age. Nat Rev Cancer 2004;4(2):97-105.
  43. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 2013;4(3):176-185.
  44. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling. Oral Oncol 2014 Oct;50(10):930-941.
  45. Guggulsterone inhibits NF-kappa B and Ikappa Balpha kinase activation, suppresses expression of antiapoptotic gene products, and enhances apoptosis. J Biol Chem 2004;279(45):47148-47158.
  46. Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak. Mol Cancer Ther 2005;4(11):1747-1754.
  47. Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Mol Cancer Ther 2005;4(12):1982-1992.
  48. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem Pharmacol 2007;74(1):118-130.
  49. Guggulsteroneinduced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase. Cancer Res 2007;67(15):7439-7449.
  50. Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts. Cancer Lett 2009;279(1):93-100.
  51. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res 2008;68(11):4406-4415.
  52. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009;30(11):1848-1856.
  53. Guggulsterone (GS) inhibits smokeless tobacco and nicotineinduced NF-κB and STAT3 pathways in head and neck cancer cells. Carcinogenesis 2011;32(3):368-380.
  54. Guggulsterone targets smokeless tobacco induced PI3K/Akt pathway in head and neck cancer cells. PLoS One 2011;6(2):e14728.
  55. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 2002;4(6):408-415.
  56. RhoC GT Pase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000;60(20):5832-5838.
  57. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 2004;6(1):R110-115.
  58. Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130(3):295-302.
  59. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000;2(5):418-425.
  60. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2006;12(15):4485-4490.
  61. Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol 2013;49(8):778-786.
  62. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003;2(10):941-948.
  63. Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARgamma. Biochim Biophys Acta 2012;1822(7):1090-1095.
  64. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010;10:365-376.
  65. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012;12(3):181-195.
  66. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 2008;73(3):709-717.
  67. Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide. Cancer Sci 2003;94(4):365-371.
  68. Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2007;25(18 Suppl):1511.
  69. Pioglitazone and risk of bladder cancer among diabetic patients in France: a opulation based cohort study. Diabetologia 2012;55(7):1953-1962.
  70. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents—implications for drug interactions. Br J Clin Pharmacol 1995;40(6):523-530.
  71. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acutephase response. Br J Cancer 2002;87(3):277-280.
  72. Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4(4):224-232.
  73. Interleukin 1β inhibits CAR induced expression of hepatic genes involved in drug and bilurubin clearance. Hepatology 2004;40(4):951-960.
  74. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology 2002;181-182:207-210.
  75. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000;274(3):707-713.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.